Partially purified TKO can also directly interact with ISGF3-y in the absence of DNA. This protein may be involved with the development of malignancies and the inability of IFN to exert its antiproliferative and antiviral effects.
3 (ISGF3), a multicomponent complex responsible for the stimulation of IFN-a-responsive genes. IFN-astimulated formation of ISGF3 and subsequent gene expression can be inhibited by phorbol esters or expression of the adenovirus ElA protein. We have investigated IFN signaling in human malignant tumor cell lines of the lung, colon, ovary, cervix, and hematopoietic organs and found some of these cells to be defective for IFN-a-induced formation of ISGF3. In many cases, an inhibitory activity termed transcriptional knockout (TKO) correlated with nonresponsiveness. TKO purified from a human papillomavirus-negative cervical carcinoma cell line has a molecular size of 19 kDa. The purified protein interacted with the ISGF3y component of ISGF3, preventing binding of ISGF3 to DNA. Purified TKO displaced ISGF3 from its DNA binding site in vitro and prevented ISGF3'y, IRF-1, and IRF-2 from interacting with the IFN-stimulated response element. Partially purified TKO can also directly interact with ISGF3-y in the absence of DNA. This protein may be involved with the development of malignancies and the inability of IFN to exert its antiproliferative and antiviral effects.
The many biological activities of interferons (IFNs) appear to be controlled at least in part by a set of cellular genes which are rapidly induced upon IFN-a or IFN--y binding to specific cell surface receptors. IFN-stimulated gene factors (ISGFs) mediate gene induction by binding to enhancers within the promoters of both IFN-a-and IFN--y-induced genes. ISGFs have been characterized, and many of these proteins have been purified and cloned (5, 12, 13, 25, 39) . Assembly and DNA binding of the ISGF3 complex follows IFN-a activation of a membrane-associated tyrosine phosphatase(s) and tyrosine kinase(s). A subset of the ISGF3 proteins, called ISGF3a, becomes tyrosine phosphorylated (7, 11, 15, 39) and associates with the 48-kDa DNA binding subunit, ISGF3-y (referred to as 48kDay to avoid confusion with ISGF3). The complex of ISGF3a and 48kDa-y completes the assembly of ISGF3, which then translocates to the nucleus and participates in the induction of IFN-activated early response genes.
Several studies indicated that growth promoters such as phorbol esters and interleukin 4, as well as certain proteins from DNA tumor viruses such as adenovirus ElA and the hepatitis B virus polymerase protein, also inhibit IFNinduced gene expression and induction of ISGF3 by IFN-a (1, 10, 14, (22) (23) (24) 32) . In the case of phorbol esters and ElA, decreased formation of ISGF3 does not appear to reflect any inability of IFN-at to modify the ISGF3a proteins (1, 14, 22, 32 ). This conclusion is based upon evidence that ISGF3 can be reconstituted by addition of excess 48kDay in nuclear extracts prepared from cells treated with IFN-a and phorbol ester or extracts from cells which express ElA (1, 14, 22, 32) . Deletion of the conserved region 1 domain of ElA abrogated ElA's inhibitory effect on ISGF3 formation. Thus, in both phorbol ester-treated and ElA-expressing cells, the 48kDay subunit of ISGF3 either is not present or is incompetent to permit assembly of ISGF3. Alternatively, an inhibitor which acts upon the 48kDay protein such that it interacts less effectively with the activated ISGF3a proteins may be present in phorbol ester-treated cells or cells expressing ElA.
The E6 and E7 proteins encoded by human papillomavirus (HPV) have many biological and structural similarities to adenovirus early proteins (28, 33, 37 Preparation of nuclear and cytoplasmic cell extracts. Nuclear and cytoplasmic cell extracts were prepared essentially as described elsewhere (32) . Selected extracts were alkylated with 10 mM N-ethylmaleimide for 20 min at room temperature followed by quenching with the addition of 15 mM dithiothreitol at 4°C.
Electrophoretic mobility shift assays (EMSAs). Gel shift assays were performed with a 32P-end-labeled doublestranded synthetic oligonucleotide (1.0 ng) with the sequence 5'GATCCATGCCTCGGGAAAGGGAAACCGAA ACTGAAGCC3' from the ISG15 (ISG with a 15-kDa product) promoter (32) . The IFN-y response region (GRR) probe was labeled in the same manner and contained the sequence 5'AGCATGTTTCAAGGATTTGAGATGTATTTCCCAG AAAAG3' (47) . The AP1 competitor oligonucleotide was purchased from Promega.
In vitro transcription and translation of 48kDa'y, IRF-1, and IRF-2 and formation of the TKO-ISGF3'y complex. The 48kDa-y protein (clone 38-1) (42), the 113-kDa ISGF3ot protein (13) , and the full-length IRF-1 (pET-IRF1) and IRF-2 (pET-IRF2) cDNAs (17) were in vitro transcribed and translated with or without [ 5S]methionine in rabbit reticulocyte lysate (Promega) according to the manufacturer's recommendation. Two microliters of translated or mock-translated protein was incubated with or without 5 ng of unlabeled ISG15 double-stranded oligonucleotide probe in standard EMSA conditions on ice for 15 min. Five microliters of buffer A (20 mM KCl; 10 mM HEPES [N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid], pH 7; 5 mM dithiothreitol; 20% glycerol) or 5 ,ul of a column fraction enriched for TKO activity was added on ice for an additional 15 min and applied to a 6% native polyacrylamide gel as described elsewhere (32) . Gels were fixed exhaustively to remove unincorporated [315]methionine, dried, and exposed on X-ray film.
Purification of TKO from C-33A cells. C-33A cells were harvested as described above, and extracts were chromatographically separated at 4°C. Active fractions were assayed by their ability to inhibit the binding of ISGF3 to the ISRE. The following resins were used to purify TKO: (i) heparinSepharose (Pharmacia) with a 0.05 to 0.3 M NaCl gradient and (ii) hydroxylapatite (Bio-Rad) with a 0 to 0.3 M Na2PO4 (pH 7.0) elution gradient. The active fractions were dialyzed against 20 mM HEPES (pH 7.0)-20 mM KCl-1 mM dithiothreitol-20% glycerol (buffer A), and (NH4)2SO4 up to 25% was added to the dialyzed material. This solution was applied to phenyl-Sepharose (Pharmacia), and the flowthrough and wash were collected, dialyzed against buffer A, and concentrated on hydroxylapatite. Purified TKO was renatured from sodium dodecyl sulfate (SDS)-13% polyacrylamide gels as described elsewhere (16) . These results were consistent with other findings that IFN-a neither induced several IFN-induced RNAs in C-33A cells nor protected them from virus infection (data not shown). ISGF3 formation in several other transformed cell lines was assayed and quantitated relative to formation of ISGF3 in diploid fibroblasts (Fig. 1B) . ISGF3 induction was diminished in both HPV-positive (HeLa, SiHa, and CaSki) and -negative (HT-3 and C-33A) cervical cancer cell lines as well as in 293 cells which express ElA. However, there were differences in the responses in that in some lines, pretreatment with IFN-y enhanced IFN-a-induced ISGF3 formation (i.e., in HeLa, SiHa, and 293 cells), whereas in other cell lines, pretreatment with IFN--y had little or no effect (i.e., in HT-3, CaSki, and C-33A cells). Interestingly, the simian virus 40 (SV40)-transformed WI-38VA13 subline (labeled WI38 in Fig. 1B ) was relatively sensitive to IFN-a induction of ISGF3. SV40 T antigen shares sequence homology and some functional similarity with the region of adenovirus ElA conserved region 1 (CR1) implicated in preventing ISGF3 formation (9, 19, 45, 49 nor adenovirus ElA appears to cause a defect in IFN-ainduced modification of the ISGF3a proteins (1, 14, 22, 32) . In fact, in vitro addition of extracts which contained excess 48kDay protein to extracts from IFN-a-treated cells which express ElA or which have been treated with phorbol myristate acetate restored formation of ISGF3 (1, 14, 22, 32) . In order to see whether the virus-negative cell line C-33A was similar to phorbol ester-treated or ElA-expressing cells, experiments were done to determine whether IFN-a-induced modification of the a peptides was intact. Similar to the results observed with phorbol ester-treated cells and those expressing ElA, addition of excess in vitro-translated 48kDa-y protein also reconstituted ISGF3 formation in nuclear extracts prepared from IFN-a-treated C-33A cells (Fig.  2A, lane 8) to levels comparable to those in diploid fibroblasts (lane 5). The effects of the addition of the 48kDa-y protein were specific in that the addition of a nonspecific control translation protein (the 113-kDa protein of ISGF3) did not reconstitute the complex (compare lanes 5 and 6 in Fig. 2A translated 48kDay (data not shown). C-33A cell extracts do not contain the 48kDa-y protein by EMSA analysis (data not shown). An independent confirmation of intact IFN-a signaling in C-33A and HeLa cells was obtained by analyzing IFN-a-induced formation of the protein complex IFN--yinduced Fc receptor factor (FcRF-y), which interacts with the GRR of the human high-affinity FcyRI gene promoter (21, 31, 47) . Although the GRR was originally defined as a region required for IFN--y-induced expression of this gene, it has been determined that both IFN--y and IFN-a can activate the protein(s) that binds to the GRR (21, 31, 47) . The tyrosine-phosphorylated 91-kDa protein found in ISGF3 is also a component of FcRF-y, while the DNA binding 48kDa-y protein is not present in the complex (21) . Since induction of ISGF3 was completely absent in C-33A cells but could be reconstituted by addition of in vitro-translated 48kDay, we examined IFN-a-induced formation of the FcRF-y complex in C-33A cells (Fig. 2B) . A similar degree of induction of the FcRF,y complex was observed in IFN-a-treated C-33A cells and diploid fibroblasts (Fig. 2B, compare lanes 2 and 4) . IFN-a also induced approximately equivalent levels of the FcRF-y complex in the other cervical cancer cell lines analyzed in Fig. 1 (data not shown). These data indicated that IFN-a binding to its receptor and activation of the tyrosine kinase which phosphorylates the 91-kDa ISGF3a protein are intact in these cervical cancer cell lines, despite the relative absence of ISGF3. Thus, in ElA-expressing, HPV-expressing, and HPV-negative cervical cancer cell lines, ISGF3 formation is defective because of a functional decrease of the 48kDa-y protein. However, the ability of IFN--y pretreatment of cells to improve IFN-a responsiveness varied between cell lines (Fig. 1) , indicating that more than one mechanism might cause the decrease in the amount of ISGF3. We decided to focus our attention on the virusnegative cell line C-33A.
RESULTS
An activity is present in cytoplasmic extracts of C-33A and HT-3 cells which displaces ISGF3 from the ISRE. One mechanism to account for the absence of ISGF3 despite intact IFN-a signaling in cervical cancer cell lines might be the presence of a specific inhibitor for ISGF3. In order to examine this possibility, unfractionated cytoplasmic extracts prepared from untreated cervical cancer cell lines were added to an ISGF3-containing nuclear extract prepared from human fibroblasts treated with IFN-a (Fig. 3A) . ISGF3 was then analyzed by EMSA. While addition of cytoplasmic extracts prepared from the HPV-positive cell lines (HeLa, SiHa, and CaSki) or human fibroblasts had little effect on ISGF3, equal amounts of protein from HT-3 or C-33A cytoplasmic extracts caused a dramatic decrease (60% to greater than 90%) in the amount of detectable ISGF3 (Fig.  3A, compare lanes 2 and 3 with lanes 4 to 7) . Initial characterization of this TKO indicated that it completely displaced ISGF3 that had been prebound to DNA in less than 1 min at 4°C. Further characterization of TKO has shown it to be heat labile and protease sensitive, but it was not inhibited by N-ethylmaleimide, RNases, or protease or phosphatase inhibitors (vanadate, NaF, okadaic acid, calyculin A, or levamisol), suggesting that it is unlikely to be a phosphatase, kinase, or protease. TKO also displaced affinity-purified ISGF3 interaction with the ISRE (data not shown (Fig. 3B ) that C-33A and HT-3 cytoplasmic extracts that decreased ISGF3 levels in the experiment described in Fig. 3A did not affect FcRF-y in that described in Fig. 3B . This result indicated both that TKO present in C-33A and HT-3 cells was specific for the ISGF3 transcription complex and that TKO did not exert its activity by interacting with the 91-kDa protein of ISGF3.
TKO disrupts binding of the 48kDa'y protein, IRF-1, and IRF-2 to the ISRE. The data presented in Fig. 3 suggested that TKO might inhibit the 48kDay component of ISGF3 from binding to the ISRE or associating with the ISGF3a proteins. To examine the former possibility, 48kDa-y was tested for its ability to interact with the ISRE in the presence or absence of TKO (Fig. 4A) . As described previously (41), 48kDa-y translated in reticulocyte lysates specifically binds to the ISRE and was displaced by the unlabeled ISRE oligonucleotide (Fig. 4A, lane 1 (17) . IRF-1 has negative growth effects and has been found to be deleted in some human leukemias (18, 46) . IRF-2 antagonizes the actions of IRF-1 and acts as an oncogene when overexpressed in NIH 3T3 cells (18) . Although ICSBP has not been shown to directly interact with the ISRE by EMSA, expression of the protein inhibited IFN-a-induced gene transcription (29) . EMSAs were done to determine whether partially purified TKO influenced the binding of in vitro-translated IRF-1 or IRF-2 to the ISRE (Fig. 4B and C) . In a manner analogous to its inhibitory effects on 48kDay binding to the ISRE, TKO clearly inhibited binding of both IRF-1 (Fig. 4B ) and IRF-2 ( Fig. 4C) to the ISRE. C-33A extracts also abrogated binding of IRF-1 and IRF-2 to the PRD1 oligonucleotide and the enhancer element within the IFN-1 promoter that binds IRF-1 and IRF-2 (17) (data not shown). As shown in Fig. 4 , there were no significant differences in the potency of the inhibitory effects of crude or partially purified TKO on binding of IRF-1, IRF-2, and the 48kDay protein to the ISRE.
Purified TKO consists of a single protein of 19 kDa. TKO activity was purified approximately 5,000-fold from extracts of C-33A cells by a combination of heparin-Sepharose, hydroxylapatite, and phenyl-Sepharose column chromatography. To identify the polypeptide associated with TKO activity, the most highly purified preparations were resolved by SDS-polyacrylamide gel electrophoresis (PAGE) and silver staining was performed (Fig. SA) . A lane adjacent to that which was silver stained was cut into slices, and proteins were eluted, renatured, and tested for TKO activity upon ISGF3 (Fig. 5B) . TKO (Fig.sB) . While the TKO activity associated with fraction 6 inhibited binding of 48kDa-y, IRF-1, and IRF-2 to the ISRE, it had no effect on the binding of FcRFe y to the GRR (Fig. SB, , and an adjacent lane was sliced into fractions. The protein(s) was eluted from the gel, renatured, and assayed for TKO activity by using ISGF3 prepared from IFN-a-treated human fibroblasts (right panel) by using a 32P-endlabeled ISRE probe. The fraction numbers are indicated on the right and above the EMSA gel in the left and right panels, respectively. Molecular weight (MW) (left panel) is given in thousands. (B) Fraction 6, which inhibited ISGF3 binding to the ISRE, and fraction 5, which was inactive, were tested for TKO activity by using in vitro-translated 48kDa-y (lanes 1 to 3), IRF-1 (lanes 4 to 6), or IRF-2 (lanes 7 to 9). As a negative control, fractions 5 and 6 were assayed for their ability to inhibit the formation of the IFN-a-induced FcRFy to the GRR (lanes 10 to 12). The arrows indicate the specific complexes formed by binding of the 48 kDa-y, IRF-1, or IRF-2 protein with the ISRE probe. lanes 2, 3, 5, 6, 8, and 9 ). This pattern of TKO activity was the same as that of the crude C-33A cytoplasmic extract shown in Fig. 3 and the partially purified TKO activity shown in Fig. 4 . TKO binds to the 48kDa'y protein. Because TKO did not appear to bind to the ISRE when assayed by EMSA (data not shown), experiments were performed to determine whether it could interact directly with the 48kDa-y protein.
The 48kDa-y protein was in vitro translated with [35S]methionine and incubated with either human fibroblast extracts or partially purified C-33A extracts enriched for TKO activity (Fig. 6A) . Formation of 48kDa-y-TKO complexes was then assessed by using nondenaturing acrylamide gels under conditions identical to those used in the EMSA. The 48kDa-y protein did not enter the gel in the absence of the unlabeled ISRE oligonucleotide (Fig. 6A, lane 1) . (The reason[s] that 48kDay does not enter the gel is not apparent.) Addition of the ISRE permitted the formation of a complex (Fig. 6A , lane 2) which was not altered in the presence of human fibroblast extract (lane 3). However, in the presence of TKO, the retarded 48kDay protein-ISRE complex disappeared and a new more slowly migrating and diffuse band formed (Fig. 6A, lane 4) . The formation of this complex did not require the presence of the ISRE oligonucleotide, since the complex was seen with the addition of TKO in the absence of DNA (Fig. 6A, compare lanes 4 and 7) . Analysis of the 35S-labeled 48kDa-y protein on SDS-polyacrylamide gels after extended incubation with TKO showed that the 48kDay protein was not degraded (data not shown). To ensure that the 48kDa-y-TKO complex which was present in the gel shown in Fig. 6A (lane 7) correlated with the ability to inhibit binding of the 48kDay protein to the ISRE, crude cytoplasmic C-33A extracts were fractionated on a heparinSepharose column. Fractions which contained TKO activity and side fractions which were devoid of activity were assayed in parallel both for the ability to disrupt the 48kDa-y-ISRE complex (Fig. 6B, upper panel) and for the ability to form a TKO-48kDa-y complex in the absence of DNA (lower panel). There was a complete correlation between fractions which inhibited binding of the 48kDa-y protein to the ISRE and the formation of the 48kDay-TKO complex. This result emphasized that TKO binding to the 48kDay protein is at least one mechanism by which TKO disrupts formation of the ISGF3 transcription complex.
Several human cancer cell lines contain a TKO activity which disrupts binding of the 48kDa'y protein to the ISRE. Although our initial studies focused on characterization and purification of TKO from the C-33A cervical cancer cell line, many other IFN-resistant cell lines derived from human cancers have been reported (4). To determine whether extracts from any other neoplastic cell lines might also contain analogous TKO activity, cytoplasmic extracts were prepared from a variety of cell lines derived from human cancers. Cytoplasmic extracts prepared from these cell lines were then added to 48kDay and assayed for their ability to inhibit binding of 48kDa-y to the ISRE, and quantitation of TKO activity from the extracts prepared from the various cell lines was performed (Fig. 7) . Although some of these cell lines clearly contained no TKO activity (Fig. 7 , columns 5 and 6), others significantly inhibited binding of 48kDay to the ISRE (columns 7 to 12). Like C-33A cells, the cell lines which contained TKO activity also showed both decreased endogenous ISGF3 formation and normal FcRF-y formation after IFN-a treatment ( Fig. 1 and 2 ) (data not shown). Whether the TKO activity observed in these human cancer cell lines is identical to that purified from C-33A cells remains to be determined. DISCUSSION IFN-induced signal transduction has been recently clarified by a number of different experimental approaches (5-7, 11, 15, 25, 38) . Although IFNs are well-described inhibitors of cell growth, the specific mechanisms by which tumor promoters, the expression of viral oncogenes, and cell transformation modulate IFN signaling remain poorly defined. Previous (1, 10, 14, (22) (23) (24) 32 Fig. 2A and 7) . The defects in ISGF3 formation seen in E1A-or HPVexpressing cells and the human malignancies examined in this study were all due to defective and/or deficient 48kDa'y. Three (Fig. 2B ). This result suggested intact tyrosine phosphorylation of the 91-kDa subunit of ISGF3, as IFN-induced tyrosine phosphorylation of the 91-kDa protein is also required to form FcRFy (20, 30, 31) . (iii) The TKO activity present in C-33A and HT-3 cells had no effect on the assembly of the FcRFy complexes (Fig. 3A) .
It should be noted that the defects of ISGF3 formation characterized in the malignant cell lines here are clearly different from the mutation in the cell line described by Velazquez et al. (43) Fig. 2 and incubated with cytoplasmic extracts (10 ,ug) at 4'C as described in the legend to Fig. 3 ISGF3 formation, the effects of IFN--y were not significant in the HPV-negative cervical cancer cell lines. The reason why treatment of C33-A, HT-3, or CaSki cells with IFN-ot after prior exposure to IFN--y did not lead to formation of ISGF3 (Fig. 2B) is not understood. The fact that cytoplasmic extracts from C-33A and HT-3 cells, but not from HPV-or ElA-positive cells, disrupted ISGF3 activity reinforced the idea that distinct phenotypes can be defined when IFN-otinduced gene expression is depressed (Fig. 3A) . The mechanism(s) by which expression of ElA (or possibly E6 and E7) renders 48kDa-y protein less capable of interacting with the ISGF3at proteins is not clear. However, it is clear that several HPV-negative cervical cancer cell lines as well as transformed cell lines derived from a wide variety of neoplasms contain an activity (TKO) which disrupts ISGF3. This activity is not present in normal cells such as fibroblasts, lymphocytes, and keratinocytes ( Fig. 3A and 7) .
Because the addition of excess 48kDa-y restored ISGF3 in C-33A cell extracts ( Fig. 2A) , it seemed likely that TKO acted upon the 48kDay subunit of ISGF3 and thus inhibited IFN-a-induced gene expression. To investigate this possibility, we purified TKO from C-33A cellular extracts. Using either highly purified preparations of TKO or the 19-kDa protein renatured from SDS-PAGE, we demonstrated that TKO prevented binding not only of 48kDay but also of IRF-1 and IRF-2 to the ISRE. Given the high degree of sequence homology among the DNA binding domains of the IRF family members, this result is not surprising (42) . The biological consequences of TKO expression with regard to the functional effects of IRF-1 and IRF-2 are under investigation. In addition, by using highly enriched C-33A-derived TKO, it was possible to demonstrate a direct interaction with in vitro-translated 48kDa-y (Fig. 6 ). Other cancer cell lines which contained TKO activity as assayed by disruption of 48kDa-y binding to the ISRE also inhibited binding of IRF-1 and IRF-2 to the same probe (data not shown). Although there is no proof that the TKO protein purified from C-33A cells is the same activity which is present in other human cancer cell lines, these results suggest that a common mechanism which can inhibit IFN-a-induced gene expression may be present in several types of transformed cells.
Thus, TKO appears to be a specific inhibitor of transcription factors involved in IFN signaling and induction of IFN-P gene expression. It is interesting to note that the IRF proteins have also been implicated as promoters and/or repressors of cell growth (18, 46) . Attempts to obtain cDNA clones corresponding to the 19-kDa protein are being made. Experiments that permit us to manipulate the expression of TKO will allow us to address some questions concerning the role of E6 and E7, ElA, and phorbol esters in modulation of IFN-a-induced gene expression and how these proteins and TKO might alter the effects of IFN-a on cell growth and transformation.
